Mahdi N A, Pathan A Z, Harrell L, Leon M N, Lopez J, Butte A, Ferrell M, Gold H K, Palacios I F
Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston 02114, USA.
Am J Cardiol. 1998 Dec 1;82(11):1345-51. doi: 10.1016/s0002-9149(98)00639-0.
Management of in-stent restenosis has become a significant challenge in interventional cardiology. The results of balloon angioplasty have been disappointing due to the high recurrence of restenosis at follow-up. Debulking of the restenotic tissue within the stents using directional coronary atherectomy (DCA) may offer a therapeutic advantage. We report the immediate clinical and angiographic outcomes and long-term clinical follow-up results of 45 patients (46 lesions), mean age 63+/-12 years, 73% men, with a mean reference diameter of 2.9+/-0.6 mm, treated with DCA for symptomatic Palmaz-Schatz in-stent restenosis. DCA was performed successfully in all 46 lesions and resulted in a postprocedural minimal luminal diameter of 2.7+/-0.7 mm and a residual diameter stenosis of 17+/-10%. There were no in-hospital deaths, Q-wave myocardial infarctions, or emergency coronary artery bypass surgeries. Four patients (9%) suffered a non-Q-wave myocardial infarction. Target lesion revascularization was 28.3% at a mean follow-up of 10+/-4.6 months. Kaplan-Meier event-free survival (freedom from death, myocardial infarction, and repeat target lesion revascularization) was 71.2% and 64.7% at 6 and 12 months after DCA, respectively. Thus, DCA is safe and efficacious for the treatment of Palmaz-Schatz in-stent restenosis. It results in a large postprocedural minimal luminal diameter and a low rate of both target lesion revascularization and combined major clinical events at follow-up.
支架内再狭窄的治疗已成为介入心脏病学中的一项重大挑战。由于随访时再狭窄的高复发率,球囊血管成形术的结果令人失望。使用定向冠状动脉斑块旋切术(DCA)对支架内的再狭窄组织进行减容可能具有治疗优势。我们报告了45例患者(46处病变)的即刻临床和血管造影结果以及长期临床随访结果,这些患者平均年龄为63±12岁,男性占73%,平均参考直径为2.9±0.6mm,因有症状的Palmaz-Schatz支架内再狭窄接受DCA治疗。所有46处病变的DCA均成功实施,术后最小管腔直径为2.7±0.7mm,残余直径狭窄为17±10%。住院期间无死亡、Q波心肌梗死或急诊冠状动脉搭桥手术。4例患者(9%)发生了非Q波心肌梗死。平均随访10±4.6个月时,靶病变血运重建率为28.3%。DCA术后6个月和12个月时,Kaplan-Meier无事件生存率(免于死亡、心肌梗死和重复靶病变血运重建)分别为71.2%和64.7%。因此,DCA治疗Palmaz-Schatz支架内再狭窄安全有效。它能带来较大的术后最小管腔直径,且随访时靶病变血运重建率和主要临床事件合并发生率均较低。